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Abstract
Fanconi anemia (FA) is a heterogeneous recessive disorder associated with a markedly elevated risk to develop cancer. To
date sixteen FA genes have been identified, three of which predispose heterozygous mutation carriers to breast cancer. The
FA proteins work together in a genome maintenance pathway, the so-called FA/BRCA pathway which is important during
the S phase of the cell cycle. Since not all FA patients can be linked to (one of) the sixteen known complementation groups,
new FA genes remain to be identified. In addition the complex FA network remains to be further unravelled. One of the FA
genes, FANCI, has been identified via a combination of bioinformatic techniques exploiting FA protein properties and
genetic linkage. The aim of this study was to develop a prioritization approach for proteins of the entire human proteome
that potentially interact with the FA/BRCA pathway or are novel candidate FA genes. To this end, we combined the original
bioinformatics approach based on the properties of the first thirteen FA proteins identified with publicly available tools for
protein-protein interactions, literature mining (Nermal) and a protein function prediction tool (FuncNet). Importantly, the
three newest FA proteins FANCO/RAD51C, FANCP/SLX4, and XRCC2 displayed scores in the range of the already known FA
proteins. Likewise, a prime candidate FA gene based on next generation sequencing and having a very low score was
subsequently disproven by functional studies for the FA phenotype. Furthermore, the approach strongly enriches for GO
terms such as DNA repair, response to DNA damage stimulus, and cell cycle-regulated genes. Additionally, overlaying the
top 150 with a haploinsufficiency probability score, renders the approach more tailored for identifying breast cancer related
genes. This approach may be useful for prioritization of putative novel FA or breast cancer genes from next generation
sequencing efforts.
Citation: Haitjema A, Brandt BW, Ameziane N, May P, Heringa J, et al. (2013) A Protein Prioritization Approach Tailored for the FA/BRCA Pathway. PLoS ONE 8(4):
e62017. doi:10.1371/journal.pone.0062017
Editor: Kwang-Hyun Baek, CHA University, Republic of Korea
Received December 20, 2012; Accepted March 15, 2013; Published April 19, 2013
Copyright: ! 2013 Haitjema et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by ENFIN, a Network of Excellence funded by the European Commission within its FP6 Programme, under the thematic area
’Life sciences, genomics and biotechnology for health’ (contract number LSHG-CT-2005-518254 to B.B. and J.H.). The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: jc.dorsman@vumc.nl
. These authors contributed equally to this work.
Introduction
Fanconi anemia (FA) is a rare recessive genetically heteroge-
neous chromosomal instability disorder with both autosomal and
X-linked inheritance. FA is associated with haematological defects,
including bone marrow failure, aplastic anemia, myelodysplastic
syndrome (MDS) and childhood acute myeloid leukemia (AML).
Besides these problems, patients have a high risk for solid tumours,
such as head and neck squamous cell carcinoma, gynaecological
squamous cell carcinoma and esophageal carcinoma. In addition,
the patients can present with liver tumours, skin tumours, brain
tumours, and renal tumours [1–4]. The high cancer risk is
generally attributed to impaired repair of DNA damage. Cells
from FA patients display chromosomal structural abnormalities.
Accordingly, patient-derived cells have turned out to be extremely
sensitive to bifunctional alkylating or DNA interstrand cross-
linking agents, such as mitomycin C or cisplatin [5,6]. The latter
feature is currently used in standard FA diagnostics.
Until now, fifteen complementation groups, FA-A, -B, -C, -D1,
-D2, -E, -F, -G, -I, -J, -L, -M, -N, -O, and -P have been described,
each corresponding to one distinct gene causing FA [7–28].
Recently, the sixteenth novel FA group was found to have
mutations in XRCC2 [29]. The FA proteins function together in
the FA/BRCA pathway, in which the monoubiquitination of
FANCD2 and FANCI is the central event. This ubiquitination
reaction is catalyzed by the so-called FA core complex, which
consists of eight FA proteins (FANC-A, -B, -C, -E, -F, -G, -L, and
-M). The activation of FANCD2 and FANCI recruits the other
factors of the pathway, FANCD1/BRCA2, FANCJ/BRIP1,
FANCN/PALB2, FANCO/RAD51C, FANCP/SLX4, and
XRCC2 to repair DNA damage (Figure 1). Beside these sixteen
FA proteins, there are several other proteins associating with the
FA core complex, but no mutations in the corresponding genes
have thus far been found. These proteins are the Fanconi Anemia
Associated Proteins (FAAPs): FAAP100, FAAP24, FAAP20,
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FAAP16/MHF1, and FAAP10/MHF2 [30–33]. A FANCD2/
FANCI associated nuclease, FAN1, was also recently identified
[34–37], as well as a deubiquitinating enzyme complex consisting
of USP1 and UAF1 [38,39]. Intriguingly, most FA proteins were
orphan proteins at the time of their discovery, showing no
homology to other proteins and harbouring few known protein
domains, while displaying a moderate evolutionary conservation.
Since not all FA patients could be linked to (one of) the sixteen
known complementation groups, new FA genes remain to be
identified. In addition, the complex FA network remains to be
further unravelled. In a previous study, bioinformatics, based on
the properties of known FA proteins, was successfully combined
with genetic linkage in identifying a novel FA gene, FANCI from a
candidate list [18].
The aim of this study is to develop an approach for the
identification of proteins of the entire human proteome that
potentially interact with the FA/BRCA pathway or are candidate
novel FA genes. To this end, we combined a bioinformatic
approach based on properties of the first thirteen identified FA
proteins with publicly available tools allowing protein ranking.
Materials and Methods
The FA proteins play a pivotal role in genome maintenance,
especially during the S phase of the cell cycle (Figure 1). The
proteins of the so-called FA core complex monoubiquitinate
FANCD2/FANCI resulting in activation of the downstream
operating FA proteins. To generate a prioritization of candidate
FA/FA-interacting proteins, an integrated approach was devel-
oped that involved screening of the entire human proteome
(EnsEMBL) using multiple publicly available bioinformatic tools
and databases. One of the sixteen known FA genes, FANCI, was
discovered via selection of genes based on (general) FA protein
properties from a limited number of ,300 candidate genes [18].
This bioinformatics strategy was incorporated in the selection
scheme, using the information of the first thirteen identified FA
proteins available at the time. This information was combined
with data from publicly available bioinformatic tools and
databases.
The entire proteome was scanned for peptides with intrinsic
properties that are shared by the first thirteen identified FA
proteins (FANC-A, -B, -C, -D1, -D2, -E, -F, -G, -I, -J, -L, -M, and
-N). The pipeline analysis started with the calculation of nuclear
localization scores (WoLF PSORT; [40]) and iso-electric points
(EMBOSS IEP; [41]). Orthology/paralogy relationships to mouse
were obtained via EnsemblCompara [42], and Gene Ontology
(GO [43]; from EnsEMBL), protein interaction data (EnVision 2),
biosemantics (Nermal; [44]) and protein function analysis
(FuncNet; including the literature mining tool iHop; [45]) were
used. The combined information was used for ranking.
Data sources and Tools
All 77454 peptides of the human protein-coding genes were
downloaded from EnsEMBL (version 56) using Biomart, together
with their corresponding EnsEMBL protein, transcript, and gene
IDs (ENSP, ENST, and ENSG). The peptides were used to score
the 22413 associated genes.
For all protein-coding genes, the associated gene name and
database, gene description, Online Mendelian Inheritance in Man
(OMIM) morbid and gene accession, and GO cellular component
terms were downloaded. The human data were linked to data on
mouse. Human to mouse and mouse to human amino acid
percentage identity, orthology type and representative (human)
protein IDs were retrieved from ComparaGene. The correspond-
ing FASTA sequences of the human proteins were used to
calculate the peptide length, iso-electric point (pI; [41]), and
Nuclear Localization Signal (NLS; [40]). The GO cellular
component annotations for the proteins were analyzed for
hierarchic relationships to nucleus (GO:0005634) with the SOAP
interface to the Ontology Lookup Service of the European
Bioinformatics Institute [46,47].
Thirteen FA proteins have been used to find interacting proteins
using the Molecular Interactions workflow of EnVision 2, Nermal
(biosemantics), and FuncNet. The UniProt IDs of the FA proteins
have been used as input to the EnVision 2 Molecular Interaction
workflow to retrieve interaction data. All thirteen FA proteins were
queried against: ChEMBL, DIP, IntAct, iRefIndex, MatrixDB,
MINT, MPIDB, Reactome, and Reactome-Functional-Interac-
tions (STRING and BioGrid were not available at the time).
Databases that returned output were: DIP, IntAct, iRefIndex,
MINT, and Reactome. Next, all UniProt/RefSeq IDs were taken
and mapped to EnsEMBL peptide IDs with the Protein Identifier
Cross-Reference service (PICR; [48]).
Nermal is a text-mining tool that predicts protein-protein
interaction based on the similarity of the context in which proteins
appear in the literature [44]. The entire matrix with the full set of
Figure 1. The Fanconi anemia pathway. For further explanation see main text (newest FA member XRCC2 not shown).
doi:10.1371/journal.pone.0062017.g001
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all human protein-pair match scores was downloaded from the
Nermal website. Since we used thirteen FA proteins, each query
protein can have interactions with more than one FA protein. In
case multiple interactions are present with the FA cluster, the
maximum score of the query protein with any of these thirteen FA
proteins was taken. Proteins interacting with one of the thirteen
FA proteins according to Nermal were listed. Further, FuncNet, a
web-based protein function prediction tool [45] was used to give
prediction scores to the whole proteome. The thirteen FA proteins
were used as reference set while the entire human proteome was
divided over several query sets. The FuncNet and Nermal scores
were integrated and a new Fisher score was calculated that
includes all FuncNet P-values as well as a P-value for Nermal.
Results and Discussion
The FA pathway consists of sixteen FA proteins and many
associating proteins. However, still unclassified FA patients exist,
which have no gene defect in any of the described complemen-
tation groups or in the associating genes/proteins. This suggests
that there are more genes/proteins involved in this pathway. Since
the unclassified patient groups are very small or even consist of a
single person, discovery of the gene by linkage analysis is hard.
Modern techniques, such as whole genome sequencing of DNA
from unclassified FA families, result in many candidate genes.
Therefore, to further elaborate which proteins participate in the
FA pathway, we used the pathway itself to screen the whole
proteome for similar proteins.
Properties of FA Proteins
During the identification of FANCI the protein properties of
existing FA proteins were used to narrow down the candidate list
generated by genetic linkage [18]. Since we could use protein
properties to distinguish more likely candidates we decided for a
genome wide approach. We first compared the intrinsic protein
properties of thirteen established FA proteins in order to
determine several ‘common’ FA ranges.
The following protein properties have been compared between
the first thirteen identified FA proteins and the latest identified FA
proteins, FANCO/RAD51C, FANCP/SLX4, and XRCC2: i)
human-mouse conservation (%ID aa); ii) Nuclear Localization
Signal (NLS) score; iii) iso-electric points (pI); iv) subcellular
localization, and v) mRNA expression patterns in normal tissues
(Table 1; first 4 criteria, all sixteen described FA proteins).
As described previously [18], a significant subset of FA genes
encoded orphan proteins at the time of their discovery. The mouse
orthologs of the FA proteins display between,50 to,80% amino
acid identity with the corresponding human protein. FANCF has
the lowest conservation with an amino acid identity of 47% with its
mouse ortholog, FANCI the highest with 80%, while the average
for 16 FA proteins is 65% (Table 1). With WoLF PSORT, a
subcellular localization prediction has been generated based on the
amino acid sequences. FA proteins with a positive NLS score are:
FANC-A, -B, -E, -M, -I, -D1, -N, -J, and -P, with an average score
of 1.42 (a score of NLS.1 means a predicted specificity of 71% of
being nuclear). The FA core complex is assembled from
subcomplexes [49], and intriguingly always one member of the
subcomplex has a positive NLS score. The score of the most
recently identified member of the FA protein family, FANCP/
SLX4, turned out to be high (4.91) in comparison to other FA
proteins. This may suggest that the prime function of FANCP/
SLX4 is in the nucleus, while other FA proteins, such as FANCA
and FANCG, may have cytoplasmic functions too.
The isoelectric point (pI) of proteins gives information about the
function of proteins. Almost all FA proteins have an acidic pI,
except FANCB (7.65) and FANCF (9.20) with the average
isoelectric point constituting 6.5. Interestingly, the pI of interacting
proteins is usually different, but together result in an optimum pH
for the desired location [50,51]. For example, the isoelectric points
of the subcomplex: FANCC-FANCE-FANCF, respectively 6.09,
4.89, 9.20, result in an average pI of 6.73.
Proteins that participate in the same pathway usually display
similar tissue-specific expression patterns. With GeneNote [52], it
is possible to survey mRNA expression levels for a selected number
of tissues. In general, the expression pattern of GeneNote profiles
for FA genes ranged between normalized intensity values of ,10–
100 and was similar between the different assayed tissues, although
the profile for FANCG was at the higher end of intensity. The
same holds true for FANCF and FANCP/SLX4, which, also for
other features, belonged to the extremes (compared to the other
FA proteins, FANCF has the highest pI, and FANCP/SLX4 the
highest NLS, see also Table 1). FANCF is also an exception in that
it is the only one-exon FA gene.
The overall picture emerging from these characterization
studies is that the vast majority of FA proteins are not highly
conserved, already previous described for FANC-A, -B, -C, -D1,
-D2, -E, -F, and -G [53]; NLSs - if present - are of moderate
strength, proteins are acidic and the corresponding mRNAs are
ubiquitously, but not highly, expressed.
Retrieval of Information and Scoring of the Complete
Proteome
The same features as queried for the FA proteins were also
interrogated for the complete human proteome. Corresponding
orthologous mouse-human identities were retrieved. The NLS and
pI scores were calculated using the peptide sequences. In addition,
other features were retrieved including whether the genes could be
linked to specific annotations, such as to Gene Ontology, but also
to MIM gene or MIM morbid. Furthermore, all proteins were
queried against the 1) Molecular Interactions workflow of
EnVision 2) the literature mining tool Nermal and 3) protein
function prediction tool FuncNet. It should be noted that in
principle for each protein/peptide, features, such as pI and NLS
scores, can be determined, while for other queries especially when
using the tools related to protein function only a subset of all
proteins queried may return results.
The ranking scheme consists of two parts, one using the protein
and another using retrieved literature data as starting point. The
first part can be further subdivided in calculable features (NLS and
pI), and other features, such as connection to Gene Ontology
terms (Table 2).
First, the FA protein properties described above were used to
aid the scoring of the whole proteome for FA-like proteins. The
settings for ranking were based on properties from the first thirteen
identified FA proteins, while the most recently identified FA
proteins, FANCO/RAD51C [26] and XRCC2 [29] were used for
validation, and FANCP/SLX4 [27,28] was used for fine-tuning.
The percentage of identity between human and mouse protein was
set between 40 and 85%. Points were given when a protein has an
identity within this range. Extra weight was given if the human
and mouse orthologs were more similar (i.e. when the difference in
percentage identity of amino acids between human-mouse and
vice versa was less than or equal to 15%). For the NLS scores, one
point was given to a protein if an NLS score #2 was detected,
which is in line with the thirteen FA proteins. However, the later
identified, FANCP/SLX4, which harbours a high NLS score,
would not obtain a score. To cover for this extreme, we developed
Protein Prioritization Approach
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Table 1. Overview of the main intrinsic protein properties of sixteen FA proteins.
Percentage identity (aa)
Gene Human-Mouse Mouse-Human NLS score pI Length (aa) Cellular localization
FANCA 65 66 0.86 6.57 1455 N/C
FANCG 72 72 20.47 5.13 622 N/C
FANCB 49 49 0.95 7.65 859 N
FANCL 78 79 20.47 6.42 375 N/C
FANCC 67 63 20.47 6.09 558 N/C
FANCE 65*EnsEMBL:41 66*EnsEMBL:53 0.70 4.89 536 N
FANCF 47*EnsEMBL:N/A 51*EnsEMBL:N/A 20.47 9.20 374 N
FANCM 63 64 0.76 6.00 2048 N
FANCD2 73 74 20.03 6.19 1471 N
FANCI 80 80 1.70 6.72 1328 N
FANCD1/BRCA2 56 58 1.02 6.70 3418 N
FANCN/PALB2 58 63 0.76 6.41 1186 N
FANCJ/BRIP1 69 74 1.13 6.91 1249 N
FANCO/RAD51C 76 75 20.47 6.73 376 N
FANCP/SLX4 51 60 4.91 5.95 1834 N
XRCC2 77 78 20.47 5.95 280 N
NLS score: Nuclear Localization Signal score. pI: iso-electric point. Cellular localization: N =Nucleus; N/C =Nucleus and Cytoplasm. *These percentages have been
calculated using RefSeq sequences as the orthologs assignment in EnsEMBL were incorrect. FANCE: EnsEMBL’s ortholog mouse protein incorrect; FANCE: NP_068741
(human: 100% identical with ENSP00000229769) and NP_001157291 (mouse). FANCF: no mouse ortholog available in EnsEMBL. FANCF: NP_073562.1 (human: 100%
identical with ENSP00000330875) and NP_001108559.1 (mouse).
doi:10.1371/journal.pone.0062017.t001
Table 2. Scoring scheme.
Filters Settings Score Remarks
Protein
% ID aa and Mouse % ID .40,85% 1.5
Difference % ID #15% 2 If %ID is in the interval (40, %ID ,85) and the difference between
human and mouse %ID is #15:0.5 point extra (2 points in total)
Peptide length #100 aa – Only peptides longer than 100 aa are scored
pI 4,pI ,9 1
NLS #2 1 The score is linearly decreased from 1 to 0 between an NLS increase
from 2 to 5
2, NLS #5 (1,0]
GO Nucleus Nucleus 1 Nucleus means GO accession equal to or descendant of nucleus
Unknown 0
Different 21
Molecular Interaction (EnVision 2) Present 1
Not present 0
Literature
MIM annotation Present 1
Not present 0
Nermal and FuncNet* Present 1.56Fisher normalized
Not present 21000
*The FuncNet and Nermal scores were integrated and a new Fisher score was calculated that includes all FuncNet P-values as well as a P-value for Nermal. The ‘‘21000’’
score is merely to clearly separate entries with Nermal/FuncNet scoring from those without. The maximum score possible with this scheme is 8.5.
doi:10.1371/journal.pone.0062017.t002
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Table 3. Top 150 genes from the combined ranking.
Position Gene Name Score Position Gene Name Score Position Gene Name Score
1 BRCA1 8.500 51 RAD51L3 6.461 101 IFIH1 6.303
2 FANCG 8.156 52 MAD1L1 6.452 102 XPA 6.301
3 FANCA 8.131 53 BIN2 6.430 103 IRF3 6.294
4 FANCC 8.005 54 KIT 6.428 104 CDKN1B 6.293
5 RPA1 7.867 55 SMARCAL1 6.426 105 ZNF217 6.290
6 BLM 7.866 56 DBF4 6.417 106 CCNO 6.290
7 FANCD2 7.854 57 STAG3 6.416 107 PRDM2 6.284
8 BARD1 7.733 58 PML 6.408 108 RFC4 6.282
9 RECQL5 7.727 59 BRIP1 6.405 109 SPO11 6.279
10 XRCC3 7.694 60 NFE2L3 6.403 110 BCL3 6.275
11 BCCIP 7.690 61 CDKN1C 6.398 111 NUP62 6.271
12 FANCL 7.635 62 PMS1 6.397 112 ITGB3BP 6.270
13 CHEK2 7.631 63 CDC25C 6.389 113 TULP3 6.269
14 FANCE 7.618 64 CDKN1A 6.384 114 ITGAE 6.261
15 NBN 7.578 65 RAD51 6.377 115 PSMD9 6.260
16 TP53 7.554 66 OGG1 6.376 116 E2F2 6.259
17 RAD52 7.508 67 CCNA1 6.375 117 NAP1L2 6.259
18 FANCB 7.500 68 RAD51C 6.372 118 MBD4 6.259
19 MDC1 7.392 69 SUMO1 6.367 119 MLF1 6.259
20 PMS2 7.358 70 TAF1B 6.361 120 RAD54B 6.257
21 FANCM 7.311 71 RTEL1 6.361 121 IFI35 6.257
22 MUS81 7.291 72 MZF1 6.357 122 REV1 6.256
23 ATRIP 7.223 73 KNTC1 6.356 123 SRA1 6.254
24 FANCI 7.214 74 CDC7 6.354 124 ELP4 6.249
25 BRF2 7.152 75 ZWINT 6.353 125 ORC2L 6.249
26 IKBKE 7.129 76 TP53BP1 6.351 126 CDC25B 6.247
27 DNA2 7.074 77 NCL 6.349 127 MDM2 6.246
28 PALB2 6.854 78 PNKP 6.344 128 NDC80 6.243
29 BUB1 6.801 79 MAP1S 6.343 129 FOXN4 6.243
30 BACH1 6.689 80 HMOX1 6.343 130 KIF11 6.242
31 DCLRE1B 6.653 81 BRCA2 6.341 131 TAF1A 6.242
32 DDX11 6.648 82 ERCC1 6.340 132 CASP8 6.240
33 DDX12 6.648 83 SFRS1 6.338 133 ERCC5 6.240
34 CCNE1 6.568 84 ATAD2 6.336 134 WDHD1 6.240
35 RAD17 6.565 85 CHRNA4 6.335 135 NCAPD3 6.238
36 NCOA3 6.558 86 CEP250 6.330 136 RNASEL 6.238
37 RAD9A 6.550 87 APEX2 6.329 137 NCOA4 6.238
38 LIG1 6.544 88 LRPPRC 6.327 138 HIF3A 6.237
39 ERCC6 6.538 89 CHFR 6.327 139 RFX5 6.237
40 RPA3 6.526 90 USP8 6.326 140 CCNF 6.233
41 GMNN 6.502 91 RBBP8 6.325 141 KLF1 6.232
42 BUB1B 6.500 92 POLR2H 6.325 142 TFDP3 6.232
43 TTF2 6.498 93 RASSF7 6.324 143 CHEK1 6.231
44 XRCC5 6.492 94 PPARGC1B 6.322 144 DAPK3 6.228
45 XRCC4 6.488 95 TRH 6.319 145 NUP153 6.228
46 XRCC2 6.486 96 FOXM1 6.317 146 UIMC1 6.228
47 NOP14 6.469 97 PRC1 6.313 147 SOD3 6.227
48 MAPT 6.468 98 NCAPH 6.307 148 NEK3 6.226
49 ZBTB32 6.463 99 SKAP1 6.307 149 FOXO4 6.224
50 UBE2T 6.463 100 TGFA 6.305 150 UBASH3A 6.224
doi:10.1371/journal.pone.0062017.t003
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a scoring in which the presence of NLS scores in the higher ranges
from 2 to 5 resulted in a linear decrease in assigned points, ranging
from 1 to 0. In total 94% of the peptides analysed displayed scores
between 20.47 and 2.00, and therefore received points. The pI
range chosen, 4,pI ,9, results in 75% of the analysed proteins
receiving a point. Since the relevance of a nuclear localization for
the DNA repair function, the presence of the GO accession
‘‘nucleus’’ or a descendant of nucleus was used to give one point.
In case no GO accession was available zero points were given,
while one point was subtracted when the accession was not
nucleus. Although the first two features evidently lack large
discriminative power, these can, nevertheless, contribute to the
overall scoring scheme and were therefore retained as parameter.
Second, we expanded the scoring of the proteome with publicly
available interaction data. If a protein in the proteome has an
interaction with at least one of the thirteen FA proteins according
to the EnVision 2 Molecular Interaction results, one point was
given. Further, a point was given when an OMIM entry was
present; this was primarily to give known genes, including those
not yet related to DNA repair pathways, a higher weight. Often,
the genes were already known for a long time (e.g. RAD51C) but
not yet related to FA. In addition, known genes in ranked lists can
be easier ruled out/or selected for often laborious further analysis
as more information is present on these genes. We also obtained
scores for the tools Nermal (biosemantics; literature mining) and
FuncNet (which includes the literature mining tool iHop). Nermal
turned out to have a good coverage of the proteome and for a
large number of proteins Nermal was the only or one of the few
tools providing a prediction. However, for other proteins FuncNet
was more informative. For ranking purposes, we therefore
included both the Nermal and the FuncNet scores.
Table 4. Scores for the sixteen known FA proteins.
Established FA protein Score
FANCG 8.16
FANCA 8.13
FANCC 8.00
FANCD2 7.85
FANCL 7.64
FANCE 7.62
FANCB 7.50
FANCM 7.31
FANCI 7.21
FANCN/PALB2 6.85
XRCC2 6.49
FANCJ/BRIP1 6.41
FANCO/RAD51C 6.37
FANCD1/BRCA2 6.34
FANCP/SLX4 5.01
FANCF 4.34*
*Manual inspection showed that the FANCF ortholog was not present in
EnSEMBL (see Table 1), therefore FANCF should have scored 2 points higher.
doi:10.1371/journal.pone.0062017.t004
Table 5. Distribution of scores in the ranked list.
Cut-off Score # Genes
$3.00 10610
$4.00 7213
$4.50 1749
$5.00 1673
$5.50 919
$6.00 868
$6.25 123
$6.50 41
$7.00 27
doi:10.1371/journal.pone.0062017.t005
Table 6. Scoring output for FA associated proteins.
Percentage identity (aa)
Associated protein Score Human-Mouse Mouse-Human NLS score pI Length* (aa) MIM Interaction GO nucleus
FAAP100/C17orf70 6.15 73 61 20.47 4.89 730 611301 – 1
USP1 5.44 88 88 1.12 5.13 785 603478 1 1
FAAP24/C19orf40 5.16 81 79 20.22 9.70 215 610884 1 21
FAN1/MTMR15 4.53 47 65 2.30 7.36 1017 – – 1
FAAP16/MHF1/APITD1 4.05 N/A N/A 0.02 7.87 164 609130 – 1
UAF1/WDR48 4.05 98 98 20.47 7.04 677 612167 – 1
FAAP20/C1orf86 2.00 30 46 20.47 8.71 283 – – 21
FAAP10/MHF2/STRA13 1.11 N/A N/A 20.47 5.69 81 – – 1
*NLS and pI based on longest peptide.
The relatively large difference in percentage identity between human-mouse and mouse-human of FAN1/MTMR15 indicates a difference in sequence length. Indeed,
upon manually checking the length for the human MTMR15 protein turned out to be 1017 aa (ENSP00000354497) and for the mouse ortholog 743 aa
(ENSMUSP00000103138). When interrogating the FAN1 ortholog at NCBI HomoloGene, both proteins were of similar length and an identity score of 71% was predicted
for human-mouse and mouse-human (Human: NP_055782.3, Mouse: NP_808561.2). The missing or wrong orthologs in EnsEMBL also contribute to the lower scoring of
FAAP16 (human-mouse 78% amino acid identity; mouse-human 83% amino acid identity) and FAAP20 (human-mouse 53% amino acid identity; mouse-human 53%
amino acid identity) and FAAP10 (human-mouse 64% amino acid identity; mouse-human 64% amino acid identity) when interrogating the orthologs at NCBI
HomoloGene.
doi:10.1371/journal.pone.0062017.t006
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Validation of the Ranking Approach
The ranking of all proteins based on FA-protein properties,
resulted in a top 150 list (Table 3). The FA proteins score in
general high, as can be expected since the scoring is based on their
properties (Table 4). Furthermore, only 1673 unique associated
gene names (including the FA proteins and proteins without a
Nermal and/or FuncNet score) score 5 points or higher (Table 5)
which is 7.5% of all unique associated gene names. The FANCF
protein scored relatively low, compared to the other FA proteins.
This could be attributed to the fact that in the automated scoring
the mouse ortholog FANCF was missing, resulting in zero points
for the human-mouse comparison feature. After manual correc-
tion of the percentage amino acid identity, FANCF ends up at the
same level as FANCJ/BRIP1 and FANCD1/BRCA2 with 6.34
points. We hypothesized that in this particular ranking, a cut-off
score $5 will select for FA like candidates (Table 4 and 5).
Since only the first thirteen FA proteins were used for pipeline
generation, we could also determine how the three newest
members of the FA protein family, FANCO/RAD51C,
FANCP/SLX4, and XRCC2 were performing (Table 4). The
overall score for FANCO/RAD51C and XRCC2 turned out to be
in the range of known FA proteins, while FANCP/SLX4 scored
lower than known FA proteins. FANCP/SLX4 has a relatively
high NLS score compared to the other FA proteins, even though
we adjusted the NLS score for extremes. In addition, at the time of
data retrieval no OMIM entry was present for SLX4.
In the case of FA, there are strong candidates for FA genes
uncovered by biochemical studies. These include the so-called
FAAP proteins [30–33], which associate to the core complex, a
nuclease FAN1 [34–37], and a deubiquitinating enzyme complex
consisting of USP1 and UAF1 [38,39]. These proteins, upon
disruption, display the FA hallmarks including MMC sensitivity.
Therefore, we were interested in how these proteins were ending
up in our ranking (Table 6). Three of these, FAAP100, USP1, and
FAAP24, would also have been suggested with our automated
ranking scheme, with a respectively score of 6.15 (rank: 299), 5.44
(rank: 890), and 5.16 (rank: 1011). The protein UAF1 is a highly
conserved in mouse (98% aa identity), and therefore had a score of
4.05 (no points for the conservation interval 40–85%). UAF1
functions as an activator of USP1 (by itself USP1 has almost no
deubiquitinating activity), and the protein complex together
functions as a deubiquitinating enzyme. Interestingly, it has been
reported that UAF1 is an abundant protein in human cells, and
that UAF1 may have additional functions [39], besides regulating
the FA pathway. For the three other FAAPs (FAAP16:4.05,
FAAP20:2.00, and FAAP10:1.11) and FAN1 (4.53), manual
correction of the orthology feature was required, as was the case
FANCF. In addition, FAAP10 was not properly scored, due to the
fact that the threshold for scoring of peptides was set at larger than
100 amino acids, and FAAP10 is 81 amino acids in length.
Overall, the chosen settings leads to logical candidates in the top.
However, awareness is important, since strong candidates may not
show up by, for example, wrong mapping of orthologs.
To further validate the method, we analyzed several proteins
that are involved in DNA repair processes that the FA/BRCA
pathway is coordinating, which include nucleolytic incision,
translesion DNA synthesis (TLS), and homologous recombination
[54] (Further see Table 7). Of the 26 analyzed proteins, 20 score
above 5 points, of which 12 are also in the top 150: BRCA1,
XRCC3, NBN/NBS1, RAD52, MUS81, XRCC2, RAD51L3/
RAD51D, RAD51, ERCC1, RBBP8/CtIP, RAD54B, and REV1
(Table 3 and 7). REV1, is involved in translesion DNA synthesis
and scores higher (6.26) than REV3 (4.22) and REV7 (3.14) that
together form a complex called Pol f, mainly because the last two
are highly conserved (more than 85%). REV1 functions as a
scaffold protein to recruit and coordinate TLS polymerase, such as
Pol f [55,56]. Pol f has besides translesion DNA synthesis another
essential role in cell proliferation [57]. The difference in score
suggest that a high score ($5) can distinguish between proteins
that have a direct interaction with the FA/BRCA pathway (USP1
and REV1) and proteins that are coordinated via this link (UAF1
and Pol f).
In addition, we investigated a prime candidate for a novel FA
gene based on whole-genome next generation sequencing data.
The particular gene, PRR12, harboured two possible pathogenic
mutations, which followed proper segregation as expected for a
recessive disorder (unpublished data). However, based on our
ranking system, this gene turned out to be an unlikely candidate,
having only 1 point. Further functional testing, confirmed that
PRR12 did not display the hallmark FA features. Upon PRR12
disruption by siRNA, the cells were still resistant to MMC.
Furthermore, downregulation of PRR12 did not result in a
reduction of RAD51 focus formation (Figure 2; Material and
Methods S1), which is characteristic for the cells of the patient in
which the PRR12 variants were found (unpublished data). This
confirmed that a low score in our ranking corresponded to a non-
FA protein (in this case).
Table 7. Overview proteins involved in processes
coordinated by the FA/BRCA pathway.
Protein Score Process*
BRCA1 8.50 homologous recombination
XRCC3 7.69 homologous recombination
NBN/NBS1 7.58 homologous recombination
RAD52 7.51 homologous recombination
MUS81 7.29 nucleolytic incision
XRCC2 6.49 homologous recombination
RAD51L3/RAD51D 6.46 homologous recombination
RAD51 6.38 homologous recombination
ERCC1 6.34 nucleolytic incision
RBBP8/CtIP 6.33 homologous recombination
RAD54B 6.26 homologous recombination
REV1 6.26 translesion DNA synthesis
EME1 6.22 nucleolytic incision
EME2 6.06 nucleolytic incision
GEN1 6.05 nucleolytic incision
RAD51L1/RAD51B 5.86 homologous recombination
MRE11A 5.57 homologous recombination
DMC1 5.52 homologous recombination
ERCC4/XPF 5.32 nucleolytic incision
RAD50 5.17 homologous recombination
RAD54L 4.75 homologous recombination
REV3/REV3L 4.22 translesion DNA synthesis
GIYD2 4.00 nucleolytic incision
SHFM1 3.76 homologous recombination
REV7/MAD2L2 3.14 translesion DNA synthesis
GIYD1 3.00 nucleolytic incision
*Information based on http://sciencepark.mdanderson.org/labs/wood/DNA_
Repair_Genes.html and [54].
doi:10.1371/journal.pone.0062017.t007
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Figure 2. Validation of FA candidate PRR12. MMC growth inhibition assays and RAD51 foci in HeLa cells after siRNA knockdown with specific
siRNAs for BRCA2, FANCD2, and PRR12 or with negative control siRNAs. A) MMC growth inhibition assays after siRNA knockdown of BRCA2 and
FANCD2 show sensitivity to MMC. siRNA knockdown of PRR12 does not result in MMC sensitivity. Data represent average values from one
representative experiment performed in triplicate. B) Relative gene expression was calculated via the 22DDCT method, normalized against the non
targeting oligo and TBP. The normalized expression (average of two different primer sets per gene) of the non targeting oligo was set at 100%, and
knockdown efficiency for BRCA2, FANCD2, and PRR12 siRNA has been indicated. C) siRNA knockdown of BRCA2 results in diminished RAD51 foci,
whereas siRNA knockdown of FANCD2 and PRR12 show RAD51 foci after knockdown. Green: aRAD51; Red: aTOPRO3.
doi:10.1371/journal.pone.0062017.g002
Figure 3. GO enrichment top 150 of Ranked, Nermal, and FuncNet. Number of genes observed with the GO terms ‘‘response to DNA damage
stimulus’’ (GO:0006974) and ‘‘DNA repair’’ (GO:0006281) in the top 150 of our combined ranking approach ‘‘Ranked’’, the literature mining tool
‘‘Nermal’’, and the protein function prediction tool ‘‘FuncNet’’. Number of genes observed, number of genes expected (P-value) for GO term
‘‘response to DNA damage stimulus’’ (GO:0006974): Ranked 71, 5 (5.50E264); Nermal 65, 5 (7.10E256); FuncNet 53, 5 (4.27E242). GO term ‘‘DNA
repair’’ (GO:0006281): Ranked 61, 4 (1.28E260); Nermal 62, 3 (1.24E262); FuncNet 47, 3 (1.54E242).
doi:10.1371/journal.pone.0062017.g003
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Furthermore, we evaluated the performance of the ranking
scheme for identification of proteins enriched for functional
classifications relevant to FA. A clear enrichment was found when
screening the top 150 of the list for GO annotations ‘‘response to
DNA damage stimulus’’ (GO:0006974; observed: 71; expected: 5;
P-value: 5.50E264) and ‘‘DNA repair’’ (GO:0006281; observed:
61; expected: 4; P-value: 1.28E260; Figure 3). To demonstrate the
effect of our combined scoring using multiple criteria, we also
compared our top 150 list (‘‘Ranked’’) to the top 150 lists of the
literature-mining tool ‘‘Nermal’’ and the protein function predic-
tion tool ‘‘FuncNet’’. When only FuncNet was used, the number of
genes with the GO annotation for ‘‘response to DNA damage
stimulus’’ (observed: 53; expected: 5; P-value: 4.27E242) and
‘‘DNA repair’’ (observed: 47; expected: 3; P-value: 1.54E242)
were clearly lower compared to our ranking. However, the top 150
of Nermal ‘‘response to DNA damage stimulus’’ (observed: 65;
expected: 5; P-value: 7.10E256) and ‘‘DNA repair’’ (observed: 62;
expected: 3; P-value: 1.24E262) results in similar number of genes
for the ‘‘DNA repair’’ annotation (Ranked: 61 genes and Nermal:
62 genes). To study the difference between our ranking (including
Nermal and FuncNet) and Nermal alone, we also analyzed the
remaining genes in the top 150 that do not have the ‘‘DNA repair’’
annotation for functional categories (Table 8 and 9). We chose for
the ‘‘DNA repair’’ term so that both lists are comparable in size
(for Ranked: 150 genes –61 genes with GO term ‘‘DNA repair’’
and 89 genes that do not have the GO term ‘‘DNA repair’’ and for
Nermal: 150 genes –62 genes with GO term ‘‘DNA repair’’ and 88
genes that do not have the GO term ‘‘DNA repair’’). In the case of
our approach, the remaining genes were significantly enriched for
cell cycle-regulated genes (10 most significant categories; all cell
cycle; Table 8). The emphasis on cell cycle parallels the important
role for FA proteins in the cell cycle. From the top 10 GO
Table 8. Top 10 biological processes for the combined ranking.
# Genes
GO-Term GO-Term id P-value Observed Expected Total
cell cycle process GO:0022402 1.24E223 38 5.33 888
cell cycle phase GO:0022403 4.00E223 35 4.41 735
mitotic cell cycle GO:0000278 2.62E222 33 3.98 663
cell cycle GO:0007049 2.33E221 40 7.04 1173
regulation of cell cycle arrest GO:0071156 8.52E216 18 1.34 223
regulation of cell cycle GO:0051726 3.32E215 25 3.51 585
cell cycle arrest GO:0007050 4.27E215 20 1.97 329
regulation of cell cycle process GO:0010564 5.08E215 20 1.99 332
negative regulation of cell cycle GO:0045786 6.90E215 21 2.31 385
cell cycle checkpoint GO:0000075 7.67E215 17 1.28 214
Biological process enrichment for the 89 remaining genes of the ranked top 150 that do not have the GO annotation ‘‘DNA repair’’ (GO:0006281). The 89 genes were
analysed for enrichment via Genomatix GeneRanker. # Genes Observed= the number of genes from the input set which have this annotation; # Genes Expected = the
number of genes one would expect to have this annotation based on the input set; # Genes Total = the number of genes from the complete genome which have this
annotation.
doi:10.1371/journal.pone.0062017.t008
Table 9. Top 10 biological processes for Nermal.
# Genes
GO-Term GO-Term id P-value Observed Expected Total
negative regulation of cellular process GO:0048523 1.10E211 38 12.18 2104
negative regulation of biological process GO:0048519 1.62E210 38 13.30 2298
cell cycle GO:0007049 2.66E208 24 6.79 1173
cell proliferation GO:0008283 4.81E208 24 7.00 1210
cell cycle process GO:0022402 1.10E207 20 5.14 888
protein modification by small protein conjugation or removal GO:0070647 1.34E207 14 2.46 425
regulation of cell proliferation GO:0042127 1.47E207 20 5.23 904
regulation of cell cycle GO:0051726 1.96E207 16 3.39 585
protein modification by small protein conjugation GO:0032446 2.20E207 13 2.17 375
negative regulation of cell cycle GO:0045786 2.97E207 13 2.23 385
Biological process enrichment for the 88 remaining genes of the Nermal top 150 that do not have the GO annotation ‘‘DNA repair’’ (GO:0006281). The 88 genes were
analysed for enrichment via Genomatix GeneRanker. # Genes Observed= the number of genes from the input set which have this annotation; # Genes Expected = the
number of genes one would expect to have this annotation based on the input set; # Genes Total = the number of genes from the complete genome which have this
annotation.
doi:10.1371/journal.pone.0062017.t009
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Figure 4. Overview genes involved in ‘‘Cell cycle process’’, Ranked vs Nermal. Analysis of the overlap between our combined approach
and Nermal for the GO biological process term ‘‘Cell cycle process’’ (GO:0022402). Top 150 of either our combined ranking or Nermal alone were
analyzed for GO term ‘‘DNA repair’’ (GO:0006281) and these genes were discarded. The remaining lists (Ranking combination scheme: 89 genes and
Nermal: 88 genes) were further compared. In total, 7 genes were found in common (BACH1, NFE2L3, DDX11, CHEK2, MAPT, BUB1B, UBASH3A). A
combined list of the remaining genes (Ranking: 81 genes and Nermal: 82 genes; total 163 genes) was analyzed with the Genomatix Pathway System
(GePS). The biological process term ‘‘Cell cycle process’’ was the most enriched (P-value: 4.83E225). The relation between the different cell cycle
proteins is depicted (red: candidates combined ranking scheme, blue: candidates Nermal).
doi:10.1371/journal.pone.0062017.g004
Figure 5. Distribution of haploinsufficiency probabilities (p(HI)). Distribution of haploinsufficiency probabilities (p(HI)) for the human
genome (from Huang et al. [61]). The mean p(HI) values for all human genes and 143 genes of our top 150 set are given as respectively, light blue and
orange circles on the x-axis. p(HI) = 1 means highly haploinsufficient, p(HI) = 0 haplosufficient.
doi:10.1371/journal.pone.0062017.g005
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enrichments obtained for Nermal, only 4 GO terms were cell-
cycle related (Table 9). The relation between the different cell-
cycle related proteins uncovered by our approach (including
Nermal and FuncNet) or with Nermal alone is shown in Figure 4.
Proteins that participate in the same pathway usually display
similar expression. As mentioned above, FA genes are expressed in
a variety of tissues, but not at very high levels (cf. GeneNote
profiles). The expression of a subset of mRNAs for FA genes is
downregulated upon serum withdrawal and, although less
strongly, upon reaching confluence, as for example tested in the
human T98G cell model [58]. Genes such as DNA2, BUB1,
DCLRE1B, DDX11 and GMNN from the top 150 list are similarly
regulated for these cell cycle features and may display an as yet not
recognized interaction with the FA network.
So far, only biallelic/recessive mutations in the genes of the
upstream branch (FANC-A, -B, -C, -E, -F, -G, -L, and -M) cause a
clinical phenotype. The downstream branch, harbouring
FANCD1/BRCA2, FANCN/PALB2, and FANCJ/BRIP1, both
biallelic and/or monoallelic mutations result in a disease
phenotype, notably breast cancer predisposition [59]. The top
candidate in our ranking BRCA1, is another breast cancer
predisposition gene. Interestingly, recently biallelic deleterious
BRCA1 mutations were discovered in a 28 year-old woman
diagnosed with ovarian cancer, who was extremely sensitive to
DNA interstrand cross-linking chemotherapy [60]. Haploinsuffi-
ciency defines the state of a given gene where a single copy is
insufficient to maintain normal function, which is one of the major
causes of dominant diseases. We used recent data from Huang
et al. (2010 [61]) to estimate the haploinsufficiency probability
p(HI) in our top 150 genes. A p(HI) of 1 indicates high probability
of haploinsufficiency, while 0 indicates haplosufficiency. We could
determine p(HI) values for 143 genes resulting in a mean
probability of 0.45 which is significantly different from the mean
of 0.29 for the whole human set for which p(HI) could be predicted
(Figure 5). To determine how the p(HI) is distributed over the 143
genes in our top 150 we plotted these against each other (Figure 6)
and both genes with low and high p(HI) were detected, as
expected. When comparing the group of genes with both a high
ranking score (.6.75), and with almost opposite p(HI) values
(,0.2 versus .0.9), four FA genes ended up in the first group,
while established breast cancer predisposition genes ended up in
the latter group. However, PALB2 has a low p(HI) value
(Table 10). Interestingly, the five genes with a ranked score above
6.75 and a p(HI) value above 0.9 (TP53, BRCA1, RPA1, BUB1,
and CHEK2) have Medical Subject Heading (MeSH) terms
for small cell carcinoma (C04.557.470.200.380) and glioblastoma
(C04.557.580.625.600.380.080.335, C04.557.470.670.380.080.
335, C04.557.465.625.600.380.080.335). These data suggest that
by overlaying the p(HI) score the top 150 can be divided in two
groups, one containing the upstream branch and related genes,
and the other group with the downstream branch related genes.
Application of Prioritization Approach
Ranking tools can be valuable to sort/sift through candidates
obtained through whole exome sequencing experiments. In
principle, the identification of a causal gene in the case of a
recessive disorder, such as Fanconi anemia, is straightforward; the
causal gene should harbour two pathogenic mutations (1 mutation
Figure 6. Distribution of scores of the top 150 vs p(HI). The scores of the top 150 of our ranked approach were plotted against the p(HI) values
of Huang et al. [61]. Shown are 143 genes, since 7 genes were not available in Huang’s data set.
doi:10.1371/journal.pone.0062017.g006
Table 10. High scoring genes versus low (,0.2) and high
(.0.9) p(HI).
Score Ranking .6.75
p(HI) ,0.2 p(HI) .0.9
PALB2 TP53
RECQL5 BRCA1
FANCB RPA1
FANCC BUB1
FANCM CHEK2
FANCE
doi:10.1371/journal.pone.0062017.t010
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in both copies). In practice, the situation may be more
cumbersome. Genes harbouring two possible pathogenic muta-
tions may turn out to be not the cause of the disease (see also
above), while genes for which only one mutation has been reported
may in fact require further study due to the fact that mutations
could be missed owing to imperfections in the sequencing
procedure, such as lack of coverage or complex mutation types
not detectable by the technique. Lists of genes harbouring only
one mutation will be inevitably significantly longer than lists of
genes harbouring two mutations. Sifting through these lists may be
significantly aided by specially tailored ranking tools which should
be combined with manual curation.
Conclusion
We show how we used publicly available bioinformatics tools
and databases to generate ranked lists tailored for FA-like genes.
While the tools by themselves can be discriminative, an integrative
approach exploiting multiple intrinsic features of FA proteins
combined with functional and text mining resources may result in
lists that are highly enriched for proteins of the network of interest.
This kind of prioritization can be useful for Next Generation
Sequencing projects to prioritize possible disease genes from an
extensive list of candidates. Furthermore, since some of the FA
proteins have been identified as genes involved in breast cancer we
believe that our prioritization strategy can also be applied in
studies to screen for breast cancer predisposition genes.
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